CDKL5 Deficiency Disorder – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
CDKL5 deficiency disorder is a genetic disorder
that causes seizures, developmental delay, and severe intellectual disability.
Seizures typically begin within a few months after birth and are difficult to
control with medications. Most children have 1 to 5 seizures every day. It is
an X-linked dominant disorder
·
This disorder includes
many of the features of classic Rett syndrome (including developmental
problems, loss of language skills, and repeated hand wringing or hand washing
movements), but also causes recurrent seizures beginning in infancy
·
Some CDKL5 mutations
change a single protein building block (amino acid) in a region of the CDKL5
protein that is critical for its kinase function. Other mutations lead to the
production of an abnormally short, nonfunctional version of the protein
·
There are currently no
approved drugs to treat CDKL5 Deficiency, save for Anti-Epileptic Drugs (AEDs)
to treat the epileptic seizures
· The anti-epileptic drugs have limited efficacy,
pointing to a strong need to develop new treatment strategies for patients
The competitive
landscape of CDKL5 Deficiency Disorder includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of CDKL5
Deficiency Disorder across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
CDKL5
Deficiency Disorder Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 ganaxolone Marinus
Pharmaceuticals Phase 3
2 Soticlestat Ovid
Therapeutics Inc. Phase 2
3 STK-001 Stoke
Therapeutics, Inc Phase 2
4 ZX008 Zogenix
International Limited, Inc., a subsidiary of Zogenix, Inc. Phase 2
5 EPX-100 (Clemizole HCl) Epygenix Phase 2
6 GWP42003-P GW
Research Ltd Phase 3
7 Lorcaserin Eisai
Inc. Phase 3
8 Cannabidiol Oral Solution INSYS
Therapeutics Inc Phase 3
Comments
Post a Comment